secwatch.observer — SEC 8-K summary
======================================

Issuer:     Profound Medical Corp. (PROF)
CIK:        0001628808
Form:       8-K
Filed at:   2026-04-01T23:59:59+00:00
Accession:  0001171843-26-002146
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Profound Medical to present TULSA-PRO data at SIR 2026 in Toronto, April 11-15
------------------------------------------------------------------------------

- Five oral presentations on April 12 during 'Men's Health 1' session at SIR Annual Meeting.
- Categorical course 'Prostate Interventions: TULSA and Beyond' on April 13 featuring TULSA.
- Presentations include CAPTAIN trial data comparing TULSA vs robotic prostatectomy for intermediate-risk prostate cancer.
- Other topics: TULSA for recurrent prostate cancer, extreme apex cancer, and automated segmentation validation.
- CEO says growing acceptance of TULSA as mainstream treatment for prostate disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628808/000117184326002146/0001171843-26-002146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628808/000117184326002146/f8k_040126.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-002146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer